'Merged' Dong-A Pharmaceutical Posts Record Third-Quarter Sales…"Growth to Continue"
Predicted impact: Low
Q3 sales up 12.7% to ₩431B, already reported in prior items.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.